Brainstem gliomas encompass a spectrum of primary central nervous system tumours arising within the midbrain, pons and medulla. Their prognosis varies from indolent low-grade lesions amenable to ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation. The ...

More recent reports of brainstem tumors include diverse sites such as the cervicomedullary junction, pons, midbrain, or the tectum. Today, these tumors are broadly categorized as either diffuse ...

A photo of co-authors from the Department of Neurosurgery, Niigata University, including Dr. Takuya Okada (middle) and Dr. Manabu Natsumeda (right of Dr. Okada). A team led by Dr. Manabu Natsumeda ...

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer IDH-mutant brainstem gliomas have a characteristic clinical and radiographic phenotype.

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Fractionated reirradiation is safe for recurrent high-grade glioma, with a median dose of 41.4 Gy and no critical structure injuries observed. Improved overall survival correlates with better ...

Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors found in the pontine region of the brainstem. Due to their high intratumoral genetic and cellular heterogeneity and ...

These tumors are less likely to spread to surrounding tissues than higher-grade tumors, so they often have better outcomes. In the past, pediatric gliomas were classified into low-grade and high-grade ...

The FDA's designation for NEO100 highlights the urgent need for treatments for pediatric-type diffuse high-grade gliomas, a rare and aggressive brain cancer. NeOnc Technologies may receive a Rare ...